Skip to main content
Clinical Trials/NCT03720353
NCT03720353
Completed
Phase 1

Pharmacological Intervention for Symptomatic Snoring

Brigham and Women's Hospital1 site in 1 country27 target enrollmentDecember 17, 2018

Overview

Phase
Phase 1
Intervention
SAS2094AH and SAS2094BH
Conditions
Snoring
Sponsor
Brigham and Women's Hospital
Enrollment
27
Locations
1
Primary Endpoint
Snoring intensity
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Currently, there is no pharmacological intervention capable of maintaining airway patency for the treatment of snoring and airflow limitation during sleep. Here we study the effect of pharmacological stimulation of the pharyngeal muscles on snoring severity, in a randomized quadruple-blind, crossover study.

Detailed Description

Two active interventions are being studied and compared against placebo. Participants will therefore be randomized to one of six possible sequences. Washout periods will be 1 week. Effects of interventions on outcomes will be assessed using mixed effect model analyses: we will quantify the effect of active treatment 1 (referenced to placebo), the effect of active treatment 2 (referenced to placebo), adjusting for effects of time (period number), carryover effects, and baseline values (fixed effects). Participants are considered random effects. Primary outcome is based on significance of active intervention 1 versus placebo.

Registry
clinicaltrials.gov
Start Date
December 17, 2018
End Date
December 10, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Scott Aaron Sands

Assistant Professor of Medicine

Brigham and Women's Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Active H

Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.

Intervention: SAS2094AH and SAS2094BH

Active L

Participants will take SAS2094AL and SAS2094BL for 10 days

Intervention: SAS2094AL and SAS2094BL

Placebo

Participants will take placebo for 10 days.

Intervention: Placebo

Outcomes

Primary Outcomes

Snoring intensity

Time Frame: 1 week

mean tracheal snoring sound intensity (tracheal microphone), decibels

Secondary Outcomes

  • Stage 1 Sleep(1 week)
  • Arousal index(1 week)
  • Visual-Analog Scale for Treatment Satisfaction(1 week)
  • Epworth Sleepiness Scale(1 week)
  • Visual-Analog Scale for Sleep Quality(1 week)
  • Flow-limitation severity(1 week)
  • Mean oxygen saturation(1 week)
  • Snoring frequency(1 week)
  • Snoring Self-Evaluation Scale(1 week)
  • Snoring Bed-Partner Evaluation Scale(1 week)
  • Flow-limitation frequency(1 week)
  • Functional Outcomes of Sleep Questionnaire(1 week)
  • "Would you keep using this medication?"(1 week)

Study Sites (1)

Loading locations...

Similar Trials